- Home
- IBG vs KTTA Comparison
IBG vs KTTA Comparison
Compare IBG & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- KTTA
- Stock Information
- Founded
- IBG 2018
- KTTA 2020
- Country
- IBG Australia
- KTTA United States
- Employees
- IBG N/A
- KTTA N/A
- Industry
- IBG Beverages (Production/Distribution)
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- KTTA Health Care
- Exchange
- IBG Nasdaq
- KTTA Nasdaq
- Market Cap
- IBG 5.4M
- KTTA 5.1M
- IPO Year
- IBG 2024
- KTTA 2021
- Fundamental
- Price
- IBG $0.55
- KTTA $0.80
- Analyst Decision
- IBG Strong Buy
- KTTA
- Analyst Count
- IBG 1
- KTTA 0
- Target Price
- IBG N/A
- KTTA N/A
- AVG Volume (30 Days)
- IBG 379.8K
- KTTA 171.7K
- Earning Date
- IBG 09-16-2025
- KTTA 08-14-2025
- Dividend Yield
- IBG N/A
- KTTA N/A
- EPS Growth
- IBG N/A
- KTTA N/A
- EPS
- IBG N/A
- KTTA N/A
- Revenue
- IBG $2,931,243.00
- KTTA N/A
- Revenue This Year
- IBG N/A
- KTTA N/A
- Revenue Next Year
- IBG N/A
- KTTA N/A
- P/E Ratio
- IBG N/A
- KTTA N/A
- Revenue Growth
- IBG N/A
- KTTA N/A
- 52 Week Low
- IBG $0.44
- KTTA $0.65
- 52 Week High
- IBG $3.35
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- IBG 41.43
- KTTA 55.44
- Support Level
- IBG $0.54
- KTTA $0.75
- Resistance Level
- IBG $0.59
- KTTA $0.91
- Average True Range (ATR)
- IBG 0.06
- KTTA 0.06
- MACD
- IBG -0.00
- KTTA 0.02
- Stochastic Oscillator
- IBG 15.24
- KTTA 52.10
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).